L-Citrulline

L-Citrulline

SCHEMBL7526760

NC(=O)NCCCC(N)C(=O)O.NCCCC(N)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.60
▸ OTC P00480 1/20 0.53
▸ DDAH1 O94760 3/20 0.49
▸ NOS2 P35228 4/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ APEX1 P27695 1/20 0.44
▸ GNAI3 P08754 1/20 0.44
▸ GNAO1 P09471 1/20 0.44
▸ GNAI1 P63096 1/20 0.44
▸ KMT2A Q03164 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ NOS3 P29474 3/20 0.42
▸ NOS1 P29475 3/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Citrulline SCHEMBL7526767 1.00 GSR (0.60) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL9107735 0.95 GSR (0.69) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL9107741 0.95 GSR (0.69) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL15909604 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL9070200 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL215403 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL20587 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL22426116 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL4542892 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19
L-Citrulline SCHEMBL15909605 0.93 OTC (0.59) GSROTCDDAH1NOS2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999983-B2 Method for producing basic L-amino acids or salts thereof by fermentation of an Enterobacteriaceae bacterium AJINOMOTO CO., INC. (JP) 2024-06-04 — — US disclosed
US-11999983-B2 Method for producing basic L-amino acids or salts thereof by fermentation of an Enterobacteriaceae bacterium AJINOMOTO CO., INC. (JP) 2024-06-04 — — US disclosed
US-11648190-B2 Toothpastes containing calcium carbonate, xanthan gum and polyacrylic acid polymer COLGATE-PALMOLIVE COMPANY (US) 2023-05-16 — — US disclosed
US-20210317487-A1 Method for Producing Basic L-Amino Acids or Salts Thereof By Fermentation of an Enterobacteriaceae Bacterium AJINOMOTO CO., INC. (JP) 2021-10-14 — — US disclosed
US-20210317487-A1 Method for Producing Basic L-Amino Acids or Salts Thereof By Fermentation of an Enterobacteriaceae Bacterium AJINOMOTO CO., INC. (JP) 2021-10-14 — — US disclosed
US-20210275413-A1 Toothpastes Containing Calcium Carbonate, Xanthan Gum and Polyacrylic Acid Polymer COLGATE-PALMOLIVE COMPANY (US) 2021-09-09 — — US disclosed
US-20210032304-A1 FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2021-02-04 — — US disclosed
EP-3752174-A1 FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF University of Florida Research Foundation, Incorporated (US) 2020-12-23 — — EP disclosed
US-20200289525-A1 Methods of Increasing Microbial Diversity of a Skin Microbiota THE PROCTER & GAMBLE COMPANY 2020-09-17 — — US disclosed
WO-2020138178-A1 METHOD FOR PRODUCING BASIC L-AMINO ACIDS OR SALTS THEREOF BY FERMENTATION OF AN ENTEROBACTERIACEAE BACTERIUM AJINOMOTO CO., INC. (JP) 2020-07-02 — — WO disclosed
WO-2013025769-A2 METHODS OF ENHANCING SKIN HYDRATION AND IMPROVING NON-DISEASED SKIN THE PROCTER & GAMBLE COMPANY (US) 2013-02-21 — — WO disclosed
CN-102600123-A New application of arginine GANG ZHI 2012-07-25 — — CN disclosed
EP-2120985-B1 FN-38 peptides for use in the treatment of psychotic and anxiety disorders AMYLIN PHARMACEUTICALS INC (US) 2012-06-27 — — EP disclosed
CN-101157720-A Template fixed peptide analogue as serine protease inhibitor POLLYFEURE CO LTD (CH) 2008-04-09 — — CN disclosed
WO-2002016626-A1 EXPRESSION VECTOR CONTAINING UREA CYCLE ENZYME GENE, TRANSFORMANT THEREOF, AND USE OF TRANSFORMANT FOR PROTEIN OVER-EXPRESSION INTERBIOGEN, INC. (KR) 2002-02-28 — — WO disclosed
CN-1258736-A Process for producing L--arginine AJINOMOTO KK (JP) 2000-07-05 — — CN disclosed
EP-0771210-A4 TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ -g(g)1 CHAIN UNIV VIRGINIA (US) 1998-12-02 — — EP disclosed
EP-0771210-A1 TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ $g(g)1 CHAIN THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 1997-05-07 — — EP disclosed
WO-1996004926-A1 TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 1996-02-22 — — WO disclosed
US-5493008-A Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 1996-02-20 — — US disclosed
Send feedback